BioSpace

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.

By BioSpace

1 min read
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights